CEL-SCI Corporation
502 articles about CEL-SCI Corporation
-
CEL-SCI Corporation Announces Upcoming Investor Conference Presentations
5/2/2018
CEL-SCI Corporation announces that Geert Kersten, Chief Executive Officer, will present at upcoming conferences.
-
CEL-SCI Corporation Reports First Quarter Fiscal 2018 Financial Results
2/13/2018
CEL-SCI reported an operating loss of ($4,911,430) for the quarter ended December 31, 2017 versus an operating loss of ($4,938,008) for the quarter ended December 31, 2016.
-
CEL-SCI to Present Tomorrow at 2018 BIO CEO & Investor Conference
2/12/2018
CEL-SCI announced that Geert Kersten, Chief Executive Officer, will be presenting at the 2018 BIO CEO & Investor Conference on Tuesday, February 13, 2018 at 9:45 a.m.
-
CEL-SCI to Present at 2018 BIO CEO & Investor Conference
2/5/2018
CEL-SCI announced that Geert Kersten, Chief Executive Officer, will be presenting at the 2018 BIO CEO & Investor Conference on Tuesday, February 13, 2018 at 9:45 a.m.
-
U.S. Patent Office Allows New CEL-SCI Patent For LEAPS Vaccine Platform Technology
1/30/2018
CEL-SCI’s patented invention relates to methods for diagnosing, preventing, and treating disease by generating or modulating the immune response through the use of specific peptides.
-
CEL-SCI Announces Adjustment to Warrant Exercise Price
1/16/2018
CEL-SCI announced today that the outstanding Series S warrants (CUSIP number 150837177) that are publicly traded under the symbol “CVM WS” on the NYSE American have been repriced to $3.00 per share of common stock for a three month period which will end on April 12, 2018.
-
CEL-SCI Awarded Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis
1/8/2018
CEL-SCI Corporation today announced that the European Patent Office has issued CEL-SCI patent EP 2254588B1 titled, “Method of Preparation and Composition of Peptide Constructs for Treatment of Rheumatoid Arthritis” for the Company’s LEAPS™(*) platform technology.
-
CEL-SCI Issues Letter to Shareholders
1/3/2018
CEL-SCI enters 2018 in a position of strength and hope for the year ahead.
-
CEL-SCI Reports Fiscal 2017 Financial Results and Clinical & Corporate Developments
1/2/2018
CEL-SCI reported a net loss of ($14.36) million in fiscal year 2017 versus a net loss of ($11.51) million in fiscal 2016.
-
CEL-SCI Announces Robert Watson Joins Its Board of Directors
12/18/2017
Mr. Watson has over 35 years of experience in the healthcare IT industry as a CEO, board member and advisor to multiple companies.
-
CEL-SCI Reaches Full Enrollment in Pivotal Phase III Head and Neck Cancer Study
12/12/2017
The primary endpoint of the study, a 10% improvement in overall survival of the Multikine treatment regimen plus Standard of Care (SOC) vs. Standard of Care alone, will be determined after a total of 298 deaths have occurred in these two main comparator arms of the study and have been recorded in the study database.
-
CEL-SCI Reports Recent Data Review By the Independent Data Monitoring Committee for Its Pivotal Phase III Head and Neck Cancer Study
12/7/2017
CEL-SCI Corporation announced today that the Independent Data Monitoring Committee (IDMC) for the Company’s pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) has completed its review of the Phase 3 study data.
-
CEL-SCI Extends the Expiration Date of Series DD and Series EE Warrants Issued in December 2016 - Nov. 28, 2017
11/28/2017
Following the Company’s reverse split in June 2017, twenty-five (25) Series DD and Series EE warrants will be required to purchase one share at an exercise price of $4.50.
-
CEL-SCI Announces Update on Arbitration Against Former Clinical Research Organization
11/13/2017
The last witness in the arbitration hearing testified on Wednesday, November 8, 2017, and no further witnesses or testimony are expected.
-
CEL-SCI Granted European Patent For Multikine's Mechanism Of Action In Making Tumors "Visible" To The Immune System
10/10/2017
-
CEL-SCI Announces Update On Ongoing Arbitration Against Former Clinical Research Organization
10/5/2017
-
CEL-SCI Announces $1.5 Million NIH SBIR Grant To Support Development Of Rheumatoid Arthritis Vaccine
9/19/2017
-
CEL-SCI Extends The Expiration Date Of Series DD And Series EE Warrants Issued In December 2016
8/29/2017
-
CEL-SCI Announces $3.5 Million Registered Direct Offering
8/23/2017
-
FDA Removes Clinical Hold On CEL-SCI’s Phase III Head & Neck Cancer Trial
8/14/2017